Serotype distribution of remaining pneumococcal meningitis in the mature PCV10/13 period : Findings from the PSERENADE Project

Simple item page
dc.contributor.authorQuesada, Maria Garcia
dc.contributor.authorSavrasova, Larisa
dc.contributor.authorPSERENADE Team
dc.contributor.institutionDepartment of Doctoral Studies
dc.date.accessioned2022-02-22T13:45:01Z
dc.date.available2022-02-22T13:45:01Z
dc.date.issued2021
dc.descriptionFunding Information: The PSERENADE project is funded by the Bill and Melinda Gates Foundation as part of the World Health Organization Pneumococcal Vaccines Technical Coordination Project, grant number INV-010429/OPP1189065. Publisher Copyright: © 2021 by the authors.
dc.description.abstractPneumococcal conjugate vaccine (PCV) introduction has reduced pneumococcal meningitis incidence. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project described the serotype distribution of remaining pneumococcal meningitis in countries using PCV10/13 for least 5-7 years with primary series uptake above 70%. The distribution was estimated using a multinomial Dirichlet regression model, stratified by PCV product and age. In PCV10-using sites (N = 8; cases = 1141), PCV10 types caused 5% of cases <5 years of age and 15% among ≥5 years; the top serotypes were 19A, 6C, and 3, together causing 42% of cases <5 years and 37% ≥5 years. In PCV13-using sites (N = 32; cases = 4503), PCV13 types caused 14% in <5 and 26% in ≥5 years; 4% and 13%, respectively, were serotype 3. Among the top serotypes are five (15BC, 8, 12F, 10A, and 22F) included in higher-valency PCVs under evaluation. Other top serotypes (24F, 23B, and 23A) are not in any known investigational product. In countries with mature vaccination programs, the proportion of pneumococcal meningitis caused by vaccine-in-use serotypes is lower (≤26% across all ages) than pre-PCV (≥70% in children). Higher-valency PCVs under evaluation target over half of remaining pneumococcal meningitis cases, but questions remain regarding generalizability to the African meningitis belt where additional data are needed.en
dc.description.statusPeer reviewed
dc.format.extent21
dc.format.extent1388972
dc.identifier.citationQuesada, M G, Savrasova, L & PSERENADE Team 2021, 'Serotype distribution of remaining pneumococcal meningitis in the mature PCV10/13 period : Findings from the PSERENADE Project', Microorganisms, vol. 9, no. 4, 738. https://doi.org/10.3390/microorganisms9040738
dc.identifier.doi10.3390/microorganisms9040738
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/7637
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85103604834&partnerID=8YFLogxK
dc.language.isoeng
dc.relation.ispartofMicroorganisms
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectGlobal
dc.subjectMeta-analysis
dc.subjectPCV impact
dc.subjectPneumococcal meningitis
dc.subjectSerotype distribution
dc.subject3.3 Health sciences
dc.subject1.6 Biological sciences
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.subjectMicrobiology
dc.subjectMicrobiology (medical)
dc.subjectVirology
dc.subjectSDG 3 - Good Health and Well-being
dc.titleSerotype distribution of remaining pneumococcal meningitis in the mature PCV10/13 period : Findings from the PSERENADE Projecten
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Serotype_Distribution_of_Remaining_Pneumococcal_Meningitis.pdf
Size:
1.32 MB
Format:
Adobe Portable Document Format
Download

Collections

Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure